tiprankstipranks
Advertisement
Advertisement
Valneva Sets May 13 Date to Present First-Quarter 2026 Results
PremiumCompany AnnouncementsValneva Sets May 13 Date to Present First-Quarter 2026 Results
1M ago
Valneva Raises Up to €84 Million via Private Placement Tied to Lyme Vaccine Milestone
Premium
Company Announcements
Valneva Raises Up to €84 Million via Private Placement Tied to Lyme Vaccine Milestone
1M ago
Valneva downgraded to Sell from Neutral at Goldman Sachs
Premium
The Fly
Valneva downgraded to Sell from Neutral at Goldman Sachs
2M ago
Pfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
PremiumMarket NewsPfizer’s (PFE) Lyme Vaccine Partner Valneva Stock Crashes 38% despite Trial Success
3M ago
Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial
Premium
The Fly
Pfizer, Valneva announce ‘positive’ results from Phase 3 VALOR trial
3M ago
Valneva Posts 2025 Results, Flags 2026 as Pivotal Year Ahead of Lyme Vaccine Phase 3 Data
Premium
Company Announcements
Valneva Posts 2025 Results, Flags 2026 as Pivotal Year Ahead of Lyme Vaccine Phase 3 Data
3M ago
Valneva Posts Stable 2025 Revenue, Sets 2026 Outlook Ahead of Key Lyme Vaccine Data
PremiumCompany AnnouncementsValneva Posts Stable 2025 Revenue, Sets 2026 Outlook Ahead of Key Lyme Vaccine Data
4M ago
Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile
Premium
Company Announcements
Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile
4M ago
Valneva and Instituto Butantan Launch Pilot Chikungunya Vaccination Campaign in Brazil
Premium
Company Announcements
Valneva and Instituto Butantan Launch Pilot Chikungunya Vaccination Campaign in Brazil
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100